Effects of Telmisartan on Early Markers of Atherosclerosis in Hypertension with and without Hyperlipidemia - ND
Active, not recruiting
- Conditions
- hyperlipidemiaMedDRA version: 6.1Level: PTClassification code 10020772
- Registration Number
- EUCTR2006-004853-38-IT
- Lead Sponsor
- AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
age 18-80 BMI <27 kg/m2 male /female not pregnant PAS >140 e <180 mmHg e/o PAD >90 mmHg e <115 mmHg total cholesterol <200 mg/dl or >250 mg/dl
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
renal failure (CK>1.8 mg/dl) epatic failure secondary hypertension secondary hyperlipidemia congestive heart failure
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: to evaluate the degree of the expression and activity of some molecules likely regulated by the the activation of the RAS system and playing a key role in the early atherosclerosis;Secondary Objective: to evaluate the effect of the AT-1 blocker telmisartan in modulating these molecules in patients with hypercholesterolemia, particularly in terms of response to treatment;Primary end point(s): to evaluate the degree of the expression and activity of some molecules likely regulated by the the activation of the RAS system and playing a key role in the early atherosclerosis
- Secondary Outcome Measures
Name Time Method